JP2019517505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517505A5 JP2019517505A5 JP2018563009A JP2018563009A JP2019517505A5 JP 2019517505 A5 JP2019517505 A5 JP 2019517505A5 JP 2018563009 A JP2018563009 A JP 2018563009A JP 2018563009 A JP2018563009 A JP 2018563009A JP 2019517505 A5 JP2019517505 A5 JP 2019517505A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- administered
- months
- dose
- lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022130733A JP2022176973A (ja) | 2016-06-02 | 2022-08-18 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
| JP2023176091A JP2024020202A (ja) | 2016-06-02 | 2023-10-11 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344866P | 2016-06-02 | 2016-06-02 | |
| US62/344,866 | 2016-06-02 | ||
| US201662382839P | 2016-09-02 | 2016-09-02 | |
| US62/382,839 | 2016-09-02 | ||
| PCT/US2017/035521 WO2017210473A1 (en) | 2016-06-02 | 2017-06-01 | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130733A Division JP2022176973A (ja) | 2016-06-02 | 2022-08-18 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517505A JP2019517505A (ja) | 2019-06-24 |
| JP2019517505A5 true JP2019517505A5 (https=) | 2020-07-16 |
| JP7641704B2 JP7641704B2 (ja) | 2025-03-07 |
Family
ID=59067913
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563009A Active JP7641704B2 (ja) | 2016-06-02 | 2017-06-01 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
| JP2022130733A Pending JP2022176973A (ja) | 2016-06-02 | 2022-08-18 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
| JP2023176091A Pending JP2024020202A (ja) | 2016-06-02 | 2023-10-11 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130733A Pending JP2022176973A (ja) | 2016-06-02 | 2022-08-18 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
| JP2023176091A Pending JP2024020202A (ja) | 2016-06-02 | 2023-10-11 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11299543B2 (https=) |
| EP (2) | EP4248989A3 (https=) |
| JP (3) | JP7641704B2 (https=) |
| KR (3) | KR102710067B1 (https=) |
| CN (1) | CN109476752A (https=) |
| AU (2) | AU2017274444B2 (https=) |
| BR (1) | BR112018074619A2 (https=) |
| CA (1) | CA3026246A1 (https=) |
| DK (1) | DK3464368T3 (https=) |
| ES (1) | ES2951650T3 (https=) |
| FI (1) | FI3464368T3 (https=) |
| HU (1) | HUE063911T2 (https=) |
| IL (1) | IL263165A (https=) |
| MX (2) | MX390955B (https=) |
| NZ (1) | NZ748650A (https=) |
| PL (1) | PL3464368T3 (https=) |
| PT (1) | PT3464368T (https=) |
| SG (2) | SG10202101062YA (https=) |
| SI (1) | SI3464368T1 (https=) |
| WO (1) | WO2017210473A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| US11299543B2 (en) | 2016-06-02 | 2022-04-12 | Bristol-Myers Squibb Company | Use of an anti-PD-1 antibody in combination with an anti-CD30 antibody in cancer treatment |
| MA50369A (fr) * | 2017-10-13 | 2020-08-19 | Seattle Genetics Inc | Modulation de la réponse immunitaire à l'aide de conjugués anticorps-médicament |
| WO2019140150A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
| WO2019217455A1 (en) * | 2018-05-07 | 2019-11-14 | Genmab A/S | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| EP3902838A4 (en) | 2018-12-26 | 2022-12-21 | Nanjing Legend Biotech Co., Ltd. | Cd30-binding moieties, chimeric antigen receptors, and uses thereof |
| KR20220069964A (ko) | 2019-09-25 | 2022-05-27 | 씨젠 인크. | 조혈암의 치료를 위한 항-cd30 adc, 항-pd-1 및 화학치료제 조합 |
| BR112022011268A2 (pt) | 2019-12-09 | 2022-09-06 | Seagen Inc | Terapia de combinação com antagonista de liv1-adc e pd1 |
| CN111407894B (zh) * | 2020-02-21 | 2022-04-29 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种治疗复发/难治t细胞淋巴瘤的新型联合靶向药物 |
| CA3183602A1 (en) * | 2020-05-13 | 2021-11-18 | Seagen Inc. | Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates |
| JP7652918B2 (ja) | 2021-03-01 | 2025-03-27 | ナントバイオ，インコーポレイテッド | 抗ｃｄ３０モノクローナル抗体及びキメラ抗原受容体 |
| CN118987233A (zh) * | 2024-08-08 | 2024-11-22 | 武汉科技大学 | 治疗经典型霍奇金淋巴瘤的药物组合物及其用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CN101490085A (zh) * | 2006-06-12 | 2009-07-22 | 特鲁比昂药品公司 | 具有效应功能的单链多价结合蛋白 |
| CL2007003622A1 (es) * | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| CA2895284A1 (en) * | 2013-02-07 | 2014-08-14 | Immunomedics, Inc. | Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer |
| DK2958941T3 (da) * | 2013-02-20 | 2019-06-24 | Innate Pharma | Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| EP3066127A1 (en) | 2013-11-06 | 2016-09-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| WO2015088847A1 (en) * | 2013-12-11 | 2015-06-18 | Glaxosmithkline Llc | Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor |
| MY184154A (en) | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| US11299543B2 (en) | 2016-06-02 | 2022-04-12 | Bristol-Myers Squibb Company | Use of an anti-PD-1 antibody in combination with an anti-CD30 antibody in cancer treatment |
| LT3463457T (lt) | 2016-06-02 | 2023-09-11 | Bristol-Myers Squibb Company | Pd-1 blokada su nivolumabu gydant atsparią hodžkino limfomą |
-
2017
- 2017-06-01 US US16/306,282 patent/US11299543B2/en active Active
- 2017-06-01 WO PCT/US2017/035521 patent/WO2017210473A1/en not_active Ceased
- 2017-06-01 MX MX2018014610A patent/MX390955B/es unknown
- 2017-06-01 SG SG10202101062YA patent/SG10202101062YA/en unknown
- 2017-06-01 KR KR1020187037834A patent/KR102710067B1/ko active Active
- 2017-06-01 CA CA3026246A patent/CA3026246A1/en active Pending
- 2017-06-01 NZ NZ748650A patent/NZ748650A/en unknown
- 2017-06-01 CN CN201780048015.7A patent/CN109476752A/zh active Pending
- 2017-06-01 EP EP23174305.5A patent/EP4248989A3/en not_active Withdrawn
- 2017-06-01 BR BR112018074619A patent/BR112018074619A2/pt not_active Application Discontinuation
- 2017-06-01 EP EP17730629.7A patent/EP3464368B1/en active Active
- 2017-06-01 HU HUE17730629A patent/HUE063911T2/hu unknown
- 2017-06-01 PT PT177306297T patent/PT3464368T/pt unknown
- 2017-06-01 PL PL17730629.7T patent/PL3464368T3/pl unknown
- 2017-06-01 FI FIEP17730629.7T patent/FI3464368T3/fi active
- 2017-06-01 SI SI201731383T patent/SI3464368T1/sl unknown
- 2017-06-01 DK DK17730629.7T patent/DK3464368T3/da active
- 2017-06-01 AU AU2017274444A patent/AU2017274444B2/en active Active
- 2017-06-01 JP JP2018563009A patent/JP7641704B2/ja active Active
- 2017-06-01 SG SG11201810454YA patent/SG11201810454YA/en unknown
- 2017-06-01 ES ES17730629T patent/ES2951650T3/es active Active
- 2017-06-01 KR KR1020237026623A patent/KR20230119265A/ko not_active Ceased
- 2017-06-01 KR KR1020247031531A patent/KR20240145059A/ko not_active Ceased
-
2018
- 2018-11-21 IL IL263165A patent/IL263165A/en unknown
- 2018-11-27 MX MX2022003571A patent/MX2022003571A/es unknown
-
2022
- 2022-04-07 US US17/715,875 patent/US20220298243A1/en not_active Abandoned
- 2022-08-18 JP JP2022130733A patent/JP2022176973A/ja active Pending
-
2023
- 2023-10-11 JP JP2023176091A patent/JP2024020202A/ja active Pending
-
2024
- 2024-10-30 AU AU2024227762A patent/AU2024227762A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517505A5 (https=) | ||
| JP2019517504A5 (https=) | ||
| JP2019503387A5 (https=) | ||
| JP2019517498A5 (https=) | ||
| PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| JP2017507155A5 (https=) | ||
| JP2018500332A5 (https=) | ||
| JP2014533279A5 (https=) | ||
| JP2019508433A5 (https=) | ||
| JP2014515036A5 (https=) | ||
| JP2019517512A5 (https=) | ||
| IL313952A (en) | Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for cancer treatment | |
| JP2021501776A5 (https=) | ||
| IL312038A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| ES2863369T3 (es) | Terapias inmunoablativas | |
| JP2022511337A5 (https=) | ||
| JP2015500822A5 (https=) | ||
| JP2021523158A5 (https=) | ||
| Cohen | Myeloma: next generation immunotherapy | |
| JP2020510039A5 (https=) | ||
| JP2021518394A5 (https=) | ||
| JP2021523233A5 (https=) | ||
| IL307925A (en) | Combination of an anti-pd-1 antibody and an anti-tissue factor (tf) antibody-drug conjugate for use in the treatment of cancer | |
| JP2014505056A5 (https=) | ||
| Sadaka et al. | Proteasome inhibition for antibody-mediated allograft rejection |